Healthcare / Drug Manufacturers - Specialty & GenericSaudi
$28.80
+0.40 (+1.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-177.5M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.4B
P/E
26.7x
↑EV/EBITDA
19.1x
↑ROE
1.8%
↑Gross Margin
49.8%
↑Debt/Equity
1.10
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+4.8%
FCF CAGR
—
FCF margin
-25.8%
FCF / Net income
-17.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.68B · net income $24.5M · FCF $-433.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.68B | $1.68B | $1.66B | $1.42B | $1.46B |
| Net Income | $24.5M | $24.5M | $-50.7M | $-165.1M | $26.5M |
| EBITDA | $252.6M | $252.6M | $161.6M | $-9.4M | $153.2M |
| EPS | 0.21 | 0.21 | -0.42 | -1.38 | 0.22 |
| Gross Margin | 49.8% | 49.8% | 42.5% | 39.9% | 42.5% |
| Operating Margin | 9.4% | 9.4% | 2.8% | -6.9% | 2.8% |
| Net Margin | 1.5% | 1.5% | -3.1% | -11.6% | 1.8% |
| Balance Sheet | |||||
| Debt/Equity | 1.10 | 1.10 | 0.81 | 0.70 | 0.70 |
| Current Ratio | 1.26 | 1.26 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-433.2M | $-433.2M | $-101.9M | $-177.5M | $2.8M |
| Returns | |||||
| ROE | 1.8% | 1.8% | -3.7% | -10.7% | 1.4% |
| Valuation | |||||
| P/E | 26.67 | 26.67 | — | — | 182.05 |
| EV/EBITDA | 19.14 | 19.14 | 34.22 | — | 37.67 |
| P/B | 2.50 | 2.50 | 3.32 | 1.76 | 2.62 |
| Growth & Yield | |||||
| Revenue Growth | 1.6% | 1.6% | 16.4% | -2.6% | — |
| EPS Growth | 150.0% | 150.0% | 69.6% | -727.3% | — |
| Dividend Yield | 1.2% | 1.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
130.0%
EPS terminal req.
$2.56
Spread vs growth
20.0%
5Y implied EPS CAGR
71.2%
EPS terminal req.
$3.09
Spread vs growth
78.8%
10Y implied EPS CAGR
37.2%
EPS terminal req.
$4.98
Spread vs growth
112.8%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.42 → 0.21
Residual
+18.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.